Name
Venoms
Accession Number
DBCAT001328
Description

Poisonous animal secretions forming fluid mixtures of many different enzymes, toxins, and other substances. These substances are produced in specialized glands and secreted through specialized delivery systems (nematocysts, spines, fangs, etc.) for disabling prey or predator.

Drugs
DrugDrug Description
ExenatideA GLP-1 agonist used in the management of type 2 diabetes mellitus.
ZiconotideAn N-type calcium channel antagonist used to manage patients with severe chronic pain who cannot tolerate, or who have not responded adequately to other treatments such as intrathecal morphine and systemic analgesics.
AncrodAn anticoagulant purified from the venom of the Malayan pit viper that functions by inactivating circulating plasma fibrinogen. Not currently approved for use or marketed in any country.
SerotoninFor temporary relief of nervousness, anxiety, mood swings, joint pains, weakness, drowsiness, itching and lethargy. Not evaluated by the FDA, homeopathic product.
CenderitideCenderitide is under investigation for the treatment of ST Elevation (STEMI) Myocardial Infarction of Anterior Wall.
CilengitideCilengitide has been used in trials studying the treatment of Sarcoma, Gliomas, Lymphoma, Leukemia, and Lung Cancer, among others.
AnfibatideAnfibatide is under investigation in clinical trial NCT01585259 (Anfibatide Phase Ib-IIa Clinical Trial).
Botulinum toxin type BA purified form of botulinum toxin type B used to block acetylcholine release in the treatment of cervical dystonia and sialorrhea.
BufotenineA hallucinogenic serotonin analog found in frog or toad skins, mushrooms, higher plants, and mammals, especially in the brains, plasma, and urine of schizophrenics. Bufotenin has been used as a...
Chlorotoxin I-131Investigated for use/treatment in various forms of brain cancer; Malignant Glioma, Glioblastoma Multiforme, GBM, Anaplastic Astrocytoma, Oligo-Astrocytoma, Gliosarcoma
alpha-Conotoxin VC 1.1Investigated for use/treatment in pain (acute or chronic).
BatroxobinNo approved indications. Batroxobin is a defibrongenating agent which has been observed to reduce fibrinogen levels and thus reduce clot risk when used intravenously.
BombesinBombesin is under investigation in clinical trial NCT01205321 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and...
NeosaxitoxinNeosaxitoxin is under investigation in clinical trial NCT01786655 (Safety Study of Long-Acting Local Anesthetic).
ChlorotoxinChlorotoxin is under investigation in clinical trial NCT00733798 (A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma).
TozuleristideTozuleristide is under investigation in clinical trial NCT02464332 (Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery).
Drugs & Drug Targets
DrugTargetType
ExenatideGlucagon-like peptide 1 receptortarget
ExenatideSerum albumincarrier
ExenatideDipeptidyl peptidase 4enzyme
ZiconotideVoltage-dependent N-type calcium channel subunit alpha-1Btarget
ZiconotideVoltage-dependent P/Q-type calcium channel subunit alpha-1Atarget
AncrodFibrinogen alpha chaintarget
SerotoninSolute carrier family 22 member 2transporter
SerotoninSodium-dependent serotonin transportertarget
Serotonin5-hydroxytryptamine receptor 2Atarget
Serotonin5-hydroxytryptamine receptor 3Atarget
Serotonin5-hydroxytryptamine receptor 3Btarget
SerotoninSynaptic vesicular amine transportertarget
Botulinum toxin type BVesicle-associated membrane protein 1target
Botulinum toxin type BVesicle-associated membrane protein 2target
Botulinum toxin type BSynaptotagmin-2target
BufotenineAmine oxidase [flavin-containing] Aenzyme